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Abstract: Quality metrics and technological advances 
for colonoscopy are contributing to detection of more 
diminutive and small adenomas, increasing the 
proportion of persons undergoing surveillance for non-
advanced neoplasia. In this issue, Kim and colleagues 
report surveillance colonoscopy findings in average-
risk Koreans who had one or more adenomas on a 
first screening colonoscopy and found a similar risk of 
metachronous advanced neoplasia between those with 
1–2 non-advanced adenoma (the “low-risk adenoma” 
group) and those with 3 or more small adenomas. The 
validity, generalizability, and clinical implications of the 
findings are considered along with recent similar studies. 
In sum, these studies support expanding the low-risk 
subgroup to include up to four diminutive tubular 
adenomas and perhaps persons with up to four small 
tubular adenomas. They also prompt consideration of 
“precision surveillance” that considers features of not 
just the polyps, but of the patient and endoscopist.
Am J Gastroenterol (2018) 113:1760–1762. https://doi.org/10.1038/s41395-018-0397-9
Surveillance colonoscopy—i.e., colonoscopy in persons with pre-
vious colorectal neoplasia—comprises an increasing part of the 
practice of gastrointestinal endoscopy, accounting for 20% of all 
colonoscopies performed in the US [1]. Guidelines for surveil-
lance have evolved over the past 30 years despite the limited evi-
dence for its effectiveness. The current US surveillance intervals 
are based on the highest degree of detected neoplasia: 3 years for 
advanced adenomas (a tubular adenoma 1 cm or larger, an ade-
noma with villous histology or high-grade dysplasia) or for 3 to 
10 non-advanced adenomas; 5–10 years for low-risk adenomas 
(1 or 2 tubular adenomas < 1 cm); and less than 3 years for more 
than 10 non-advanced adenomas [2]. The goal of surveillance it 
do reduce colorectal cancer (CRC) incidence and mortality. Since 
studies of surveillance with these hard outcomes are challeng-
ing logistically, we use the surrogate outcome of metachronous 
advanced neoplasia (AN), which included advanced adenomas 
and CRC. Established risk factors for metachronous AN include 
older age, male sex, baseline findings (the number, size, and his-
tology of adenomas), and location in the proximal colon [3]. In 
practice, only the polyp findings determine the surveillance inter-
val, which may be a reason for their relatively poor discrimination 
for estimating risk of metachronous AN [4], particularly in this 
era of “personalized medicine”.
Patients with low-risk adenomas dominate surveillance, yet it is 
this subgroup for which the effectiveness of surveillance is espe-
cially uncertain. High definition colonoscopes and quality metrics 
such as the adenoma detection rate (ADR) have likely contributed 
to the increased detection of adenomas, expanding the pool of 
patients for surveillance. And with detection of more diminutive 
(≤5 mm) and small (6–9 mm) adenomas, the subgroup with 3 or 
more non-advanced adenomas is expanding, increasing the pro-
portion of patients for which a 3-year surveillance interval is rec-
ommended. While we await results of European trials of different 
surveillance intervals [5], information on the metachronous risk 
of AN in this subgroup could be useful for informing surveillance 
practice.
In this issue, Kim et al. [6] report the surveillance colonos-
copy findings of a cohort of 5482 average-risk Korean patients 
who had one or more adenomas on a first screening colonoscopy. 
Baseline findings were categorized into one of four groups: 1–2 
non-advanced adenomas (Group 1); 3 or more non-advanced 
diminutive adenomas (Group 2); 3 or more small adenomas (Group 
3), and; advanced adenomas (Group 4). After a median follow-up 
of 38 months, metachronous AN was found in 3.9%, 5.9%, 10.6%, 
and 22.1%, respectively. For Groups 1 and 2, the 95% confidence 
intervals (CIs) overlap (3.3–4.5% and 3.9–8.0%, respectively), 
suggesting “no difference” statistically, although the 2.0% abso-
lute difference might be considered clinically important by some 
providers and patients. Incident CRC was diagnosed in 2 (0.05%) 
and 1 (0.21%) members of Groups 1 and 2, respectively. The inves-
tigators adjusted their risk estimates for metachronous AN for 
confounding factors—something we don’t do in clinical practice, 
but perhaps should. After adjusting for age, sex, body mass index 
(BMI), smoking status, alcohol consumption, regular exercise, reg-
ular aspirin use, bowel preparation quality, and ADR of both the 
screening and surveillance endoscopists, they found hazard ratios 
(HR) of 1.71 (CI, 0.99–2.94) for Group 2, 2.76 (CI, 1.72–4.44) for 
Group 3, and 5.23 (CI, 3.57–7.68) for group 4 relative to Group 1, 
which served as the reference group. Factors independently 
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associated with metachronous AN were age, male sex, ADR of 
both endoscopists, and the baseline findings of Groups 3 (mul-
tiple small adenomas) and 4 (advanced adenoma). For group 2 
(multiple diminutive adenomas), the multivariable P-value was 
0.059—just missing the 0.05 threshold for model retention. The 
investigators interpreted these findings as showing “borderline 
increased risk of metachronous AN” in patients with 3 or more 
non-advanced diminutive adenomas compared with patients with 
low-risk adenomas, and offered that the “optimal surveillance 
interval” for Group 2 patients may be lengthened. This study raises 
several questions: How valid and generalizable are the study find-
ings? How do the findings fit with recently published studies? How, 
if at all, do the findings affect our thinking about surveillance in 
general and our management of patients with multiple diminu-
tive non-advanced adenomas more specifically? In what direction 
should it move surveillance research?
The study investigators are commended for identifying a large, 
homogeneous group (5482 average-risk persons 50 and older who 
had one or more adenomas on index screening colonoscopy) and 
for their thoughtful analysis, which attests to the importance of 
considering both patient factors and procedure factors (and not 
just the polyps). A limitation potentially affecting study validity 
is the interval between screening and surveillance colonoscopy. 
The median interval was 38 months overall, but for Groups 1 to 4, 
it was 38, 33, 33, and 36 months. These median intervals suggest 
that surveillance was performed sooner than usual in many cases 
and for Group 1 in particular, where a 5–10 year interval is recom-
mended [2]. The effect of this sooner-than-recommended surveil-
lance for Group 1 is underestimation of the (5 to 10 year) risk of 
metachronous AN, increasing the chances of finding a difference 
between Groups 1 and 2. Had the median surveillance interval for 
Group 1 been closer to even 4 years, the “borderline” difference in 
metachronous AN risk would likely have been smaller or even nil 
clinically and not close to significance statistically, strengthening 
the suggestion that an interval longer than 3 years is reasonable 
for Group 2. A second potential limitation is that the study cohort, 
while homogeneous clinically, is comprised of persons with base-
line adenomas who showed up for surveillance. Due to the retro-
spective study design, we don’t know how well they represent all 
persons with adenomas on index screening colonoscopy from that 
timeframe; it is possible that the risk for metachronous AN differs 
between those who had versus did not have surveillance. Whether 
the study cohort’s risk for subsequent neoplasia is higher, lower, or 
no different from the non-adherent group is unknown. Further, 
the generalizability of the study findings to populations from other 
countries is uncertain; in general, the prevalence of colorectal neo-
plasia and risk factor profiles of Western populations are higher.
Despite the concerns about validity and generalizability, the 
study’s findings are consistent with recent studies that have exam-
ined the yield of surveillance in subgroups of persons with non-
advanced adenomas. In a retrospective cohort study of 1414 
patients with adenomas, Vermulapalli and Rex found no differ-
ence in metachronous AN risk between persons with 1–2 ver-
sus 3–4 tubular adenomas < 10 mm [7]. Among persons whose 
largest adenoma was 6–9 mm, Arbib et al. found a 9.8% risk of 
metachronous AN in both 1–2 and 3–9 polyp groups [8]. AN risk 
was greater in those with small versus diminutive polyps, however, 
regardless of polyp number. In a multisite, retrospective cohort 
study, Moon et al. found no difference in metachronous AN risk 
between a low-risk adenoma group of 1–2 adenomas < 10 mm 
(n = 1384) and groups with 3–10 diminutive tubular adenomas 
with (n = 145) and without (n = 117) 1–2 small adenomas (respec-
tive hazard ratios of 1.30 [CI, 0.59–2.87] and 1.56 [CI, 0.83–2.92]) 
[9]. The hazard ratios were adjusted for several (risk factor) covari-
ates, including age, sex, BMI, smoking, and regular use of aspirin/
NSAIDs, among others. Finally, in 2570 patients with 1 or more 
adenomas at index colonoscopy, Park et al. found no difference in 
risk of metachronous AN between a group of 999 patients with 
1–2 non-advanced adenomas and a group of 351 patients with 
3–4 non-advanced adenomas (2.8% and 2.6%, respectively) [10]. 
In sum, these studies suggest that the low-risk adenoma group 
could include up to four diminutive tubular adenomas; and per-
haps include persons with up to 4 small (i.e., 6–9 mm) tubular 
adenomas.
Revised guidelines for surveillance are expected soon; it will be 
interesting to see whether the surveillance interval of 5–10 years is 
extended to 10 years for the current low-risk adenoma group, given 
recent evidence that supports doing so [11, 12]. And will the low-
risk adenoma group be extended to include persons with more than 
two non-advanced adenomas or will an “intermediate” group be 
recognized that includes persons with more than two diminutive 
and/or small non-advanced adenomas? As colonoscopic screening 
and surveillance continue to mature and as electronic databases 
with large numbers of subjects undergoing surveillance proliferate, 
we will see more studies on the yield of surveillance in adenoma 
subgroups. Some of these studies, like that of Moon et al. [9], will 
include risk estimates that consider and adjust for phenotypic and 
procedural factors. In contained health care systems, some studies 
will link baseline findings and surveillance to harder clinical end-
points of CRC incidence and mortality. Both individual studies of 
these kinds and meta-analyses of them that consider well-defined 
polyp subgroups may eventually move surveillance toward more 
tailored, personalized intervals. And since ADR of both baseline 
endoscopist and surveillance endoscopist have been shown to affect 
findings [13], these factors will be important to consider as well 
when deciding whether and when further colonoscopy is required. 
Surveillance in the future may be determined by a combination 
of patient phenotypic factors and exposures, baseline endoscopic 
findings, and quality metrics of endoscopists. To achieve this clini-
cally sensible practice, software applications and systems that can 
identify and integrate these factors will be required. A prototype 
has been developed for CRC screening and surveillance [14], but 
requires additional development, integration with the electronic 
medical record and other databases, and further testing. The cur-
rent study by Kim et al. may move the needle on extending the 
surveillance interval for a growing subgroup of persons with non-
advanced adenomas. More importantly, it prompts us to consider 
future surveillance, where we understand its benefits and limi-
tations more clearly, and tailor the interval based on more than 
just adenomas. We anticipate that such “precision surveillance” 
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will improve the balance between benefit and risk for individual 
patients, and increase the yield, precision, efficiency, and effective-
ness of surveillance for the population as a whole.
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